Yunnan Botanee Bio-Technology Group Co., Ltd. Class A

Yunnan Botanee Bio-Technology Group Co., Ltd. Class A

SSZSE:300957
27.07
CNY
+0.02
(+0.07%)
1.30EPS
25.11P/E
13.85BMarket Cap
Apr 23Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.88
2.93
5.38
7.32
9.88
11.83
13.06
13.68
12.72
13.25
Basic EPS, GAAP
0.36
0.62
1.14
1.51
2.12
2.48
1.79
1.2
1.2
1.3
Free Cash Flow per Basic Share
0.45
0.17
1.26
0.95
2.17
0.98
0.8
0.75
1.17
- -
Dividend per Share
- -
0.09
0.53
0.28
0.47
0.6
0.8
0.63
0.63
0.84
Book Value per Share
0.71
1.24
2.1
3.33
11.23
13.11
13.84
14.28
14.54
14.27
Tangible Book Value per Share
0.7
1.17
1.97
3.18
11.07
12.92
12.4
12.91
12.54
12.28
Basic Weighted Avg Shares
424
424
361
360
407
424
423
419
421
417
Sales/Revenue/Turnover
798
1,240
1,944
2,636
4,022
5,014
5,522
5,736
5,359
5,532
Operating Margin (%)
23.97
25.86
26.46
25.05
24.68
22.76
15.27
10.04
10.71
11.54
Depreciation Expense
5
7
12
14
59
93
138
190
215
- -
Net Income, GAAP
154
261
412
544
863
1,051
757
503
506
544
Effective Tax Rate (%)
16.64
16.05
17.76
16.07
15.11
13.46
12.62
18.67
16.17
15.86
Profit Margin (%)
19.25
21
21.19
20.61
21.45
20.97
13.7
8.77
9.44
9.83
Working Capital
226
352
628
972
4,325
4,723
4,231
4,615
4,313
4,130
LT Debt
- -
- -
- -
53
76
51
68
440
283
332
Total Equity
262
451
761
1,202
4,778
5,602
6,016
6,188
6,305
6,130
Return on Invested Capital (%)
- -
68.98
65.44
50.74
27.16
19.37
12.62
7.56
7.38
7.81
Return on Capital (%)
- -
72.38
66.99
52.98
27.97
19.89
12.7
7.94
7.21
8.06
Return on Common Equity (%)
- -
74.43
68.58
55.59
28.99
20.4
13.26
8.45
8.29
8.99

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
658
483
405
LT Borrowings
207
233
278
LT Finance Leases
62
57
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
424
424
424
Market Capitalization
16,076
13,348
13,852

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,800
5,696
5,455
Cash, Cash Equivalents & STI
4,221
4,159
3,897
Accounts Receivable, Net
498
459
442
Inventories
592
686
758
Total Current Liabilities
1,600
1,482
1,325
Payables & Accruals
- -
- -
- -
ST Debt
658
483
405
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
65.39%
1.89%
Free Cash Flow
- -
27.26%
55.97%
Net Income, GAAP
- -
3.92%
0.53%
Sales/Revenue/Turnover
- -
16.93%
-6.58%
Total Cash Common Dividend
- -
26.39%
1.19%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,097
1,708
1,213
1,718
5,736
2025
949
1,423
- -
1,894
5,359
2026
1,118
1,474
1,046
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.73
-0.16
0.21
1.2
2025
0.07
0.52
- -
0.56
1.2
2026
0.16
0.54
0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.6
0.01
0.01
0.63
2025
0.01
0.61
- -
- -
0.63
2026
0.24
0.43
0.16
- -
- -

Company Description

CEO
Zhen Yu Guo
Full Time Employees
3,574
Sector
Consumer non-durables
Industry
Household/Personal care
Address
No. 53, Keyi Road Kunming YU China 650106
IPO Date
Mar 25, 2021
Business
Yunnan Botanee Bio-Technology Group Co.LTD is a Chinese health industry company primarily engaged in the research, development, production, and sales of skincare and cosmetic products as well as specialized medical devices. The company's core product lines include facial creams, lotions, masks, essences, sunscreens, powders, BB creams, makeup removers, and other skin care and cosmetic categories. It also develops medical devices featuring hyaluronic acid-based biofilms and dressings designed for the protection and care of skin barriers damaged by minimally invasive surgical procedures. The company markets its products under several brand names including Winona, Winona Baby, AOXMED, Beforteen, Za, and PURE&MILD, distributing through both offline and online channels. Additionally, Botanee produces household electronic radio frequency beauty equipment. Founded in 2010 and headquartered in Kunming, China, Yunnan Botanee Bio-Technology Group has established itself as a "Skin Health Internet+" big health industry group, driving innovation by leveraging advanced technologies in dermatology, biology, and botany with a focus on active ingredients derived from unique Yunnan plateau plants. The company successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market in March 2021. Significant recent developments include the official operation commencement of its new central factory base, which enhances the company’s independent production capacity and consolidates its foundational development. Botanee has actively expanded its research and industrial design capabilities, earning national recognition such as the National Industrial Design Center designation and the National Technological Innovation Demonstration Enterprise title. In early 2024, the company received accolades including the "Best Listed Company 2024" and "Best Practice in Investor Relations Management for Listed Companies," alongside an AAA ESG industry rating, underscoring a commitment to sustainability and corporate governance. The company has also seen recent ownership adjustments including a 2.5% stake acquisition by a group of buyers from Tianjin Sequoia Juye Equity. Botanee continues to innovate within the skin health ecosystem and expand its product offerings and market reach across China. The company operates through various subsidiaries and joint ventures focused on specialty plant extraction, health technology, and medical biotechnology sectors, reinforcing its integrated approach to health and beauty products formation and distribution. This positions Yunnan Botanee Bio-Technology Group as a comprehensive player in China's skin health and cosmetic industries with an emphasis on medical-grade product innovations and scalable manufacturing infrastructure.